Center for Environmental and Health Effects of PFAS

PFAS 环境与健康影响中心

• 批准号: 10208368
• 负责人: CAROLYN J MATTINGLY
• 金额: $ 30.44万
• 依托单位: NORTH CAROLINA STATE UNIVERSITY RALEIGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-15 至 2025-01-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10208368
• 关键词: 2019-nCoV; Address; Adopted; Age; Air; Animals; Antibodies; Antibody Response; Antibody titer measurement; Blood; Blood specimen; COVID-19; Chemicals; Collection; Communities; Complement; Cross-Sectional Studies; Data; Disease; Enrollment; Environmental Health; Exposure to; Fright; Funding; Gender; Goals; Health; Health Personnel; Human; Immune response; Immunoglobulin G; Immunosuppression; Individual; Infection; Internet; Measurement; Measures; Medical; Medical History; National Toxicology Program; Nongovernmental Organizations; North Carolina; Outcome; Participant; Plants; Population; Population Heterogeneity; Prevalence; Prospective Studies; Public Health; Questionnaires; Race; Research; Risk; Sample Size; Sampling; Serum; Severity of illness; Specimen; Superfund; Surveys; Symptoms; Telephone; Testing; Time; Vaccine Design; Vaccines; Virus; Water; Work; adverse outcome; cohort; coronavirus disease; cytokine release syndrome; design; drinking water; epidemiology study; experience; falls; immune function; immunotoxicity; infection rate; interest; novel; parent grant; population based; prevent; response; study population; vaccine response

Project Summary/Abstract This project expands the GenX Exposure Study funded through the NC State Center for Environmental and Health Effects of PFAS to answer urgent questions related to per-and polyfluoroalkyl substances (PFAS) exposure and their impacts on SARS-CoV-2 response. PFAS as a class are associated with immune suppression as evidenced in humans by lower antibody titers to common vaccines in higher exposed individuals. Using the GenX Exposure Study, a prospective study of 1,000 PFAS exposed individuals, we plan to answer two questions: 1) what is the prevalence of overt disease, symptoms, sequelae, and antibodies in this population? and 2) does PFAS exposure modify response to virus as measured by antibodies? This study, located in the Cape Fear Region of North Carolina, includes participants ranging in age from 8-86 years with diverse demographic and medical histories. PFAS levels in this study are much higher than the national values for PFAS measured; in this population, novel fluoroethers have been measured in serum and represent ~25% of the overall PFAS levels in serum. In this population, we plan to collect two blood samples for SARS-CoV-2 antibody testing, once in the fall of 2020 and again in the summer of 2021. Additionally, we will administer a survey related to COVID 19 disease and symptoms at five points in time during this one-year study to capture the ongoing disease experience of the cohort. We currently anticipate a prevalence of antibody positive infection of 10% (June 2020); we expect this to increase as the rates of infection are increasing in North Carolina. We will use PFAS values measured in Fall 2020 to assess the impact of PFAS exposure and SARS-CoV-2 response in cross-sectional analyses; we will use the same PFAS measures to assess PFAS exposures on these outcomes in a longitudinal fashion for data collected following PFAS measurement. With 1000 participants, this will be one of the largest studies to date regarding PFAS exposure and immune response as measured by antibodies. Given that PFAS suppress immune function, exposure may result in worse disease because individuals fail to make sufficient antibodies to the virus, or may result in milder disease since the so-called “cytokine storm” may be mitigated by poorer immune response. Our study will provide the survey data combined with antibody data and stored specimens to further explore how PFAS influence COVID. If a vaccine becomes available and is adopted during our study, we will shift our focus to vaccine response. We plan to work with our community partners both local non-governmental organizations and health departments to share results with study participants and the community in a timely fashion. This supplement complements the ongoing research at the NC State Superfund Center and allows us to leverage an ongoing epidemiological study to address this important public health issue.

项目摘要/摘要 该项目扩展了通过NC国家环境中心资助的GenX暴露研究和 PFA回答与每种多氟烷基物质（PFAS）暴露有关的紧急问题的健康影响 它们对SARS-COV-2响应的影响。 PFA作为班级与免疫抑制有关 通过对较高暴露的个体中常见疫苗的较低抗体滴度。使用Genx暴露研究， 对1,000个PFA暴露个人的前瞻性研究，我们计划回答两个问题：1） 该人群中的明显疾病，症状，后遗症和抗体？ 2）PFAS暴露会改变对 通过抗体测量的病毒？这项研究位于北卡罗来纳州开普恐惧地区，包括参与者 从8-86岁的人群和医学历史上看，年龄从8-86岁不等。这项研究中的PFA水平很多 高于测量的PFA的国家价值；在这个人群中，已经在连续的 并表示血清中PFA总体水平的约25％。在这个人群中，我们计划为 SARS-COV-2抗体测试，一次是在2020年秋天和2021年夏季。此外，我们将管理 在这项为期一年的研究中，与COVID 19疾病和症状有关的调查五个时间点，以捕获 持续的疾病经验。我们目前预计抗体阳性感染的患病率为10％ （2020年6月）;我们预计，随着北卡罗来纳州的感染率增加，这会增加。我们将使用PFAS值 在2020年秋季测量，以评估PFAS暴露和SARS-COV-2反应在横截面分析中的影响； 将使用相同的PFA测量值以纵向方式评估有关这些结果的PFA暴露 在PFA测量后收集。对于1000名参与者，这将是迄今为止最大的研究之一 通过抗体测量的PFAS暴露和免疫响应。鉴于PFA抑制免疫增强功能，暴露 由于个人无法对病毒产生足够的抗体，或者可能导致米勒 疾病由于所谓的“细胞因子风暴”可以通过较差的免疫反应来减轻。我们的研究将提供 调查数据与抗体数据和存储标本相结合，以进一步探索PFA的影响如何影响COVID。如果a 疫苗可用并在我们的研究期间采用，我们将把重点转移到疫苗反应上。我们计划工作 与我们的社区合作伙伴一起，当地的非政府组织和卫生部门都与 及时学习参与者和社区。这种补充完成了正在进行的研究 NC国家超级基金中心，允许我们利用正在进行的流行病学研究来解决这一重要公众 健康问题。